We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-21.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.48B
AUM Growth
-$2.59B
Cap. Flow
-$1.26B
Cap. Flow %
-13.32%
Top 10 Hldgs %
78.76%
Holding
139
New
5
Increased
29
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$300M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$200M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$81.4M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$68.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$313M
2
GILD icon
Gilead Sciences
GILD
+$25.3M
3
MDVN
MEDIVATION, INC.
MDVN
+$12M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$4.31M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.11M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.5B
$1.7B 17.96%
23,498,460
+4,023,144
+21% +$300M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.52B 16%
43,235,267
+5,941,539
+16% +$200M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$911M 9.61%
6,542,599
– –
ABBV icon
4
AbbVie
ABBV
$472B
$821M 8.66%
14,373,538
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$677M 7.14%
24,213,838
+3,732,396
+18% +$81.4M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$396M 4.18%
4,806,483
+691,400
+17% +$56.3M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$338M 3.57%
13,659,832
+568
+0% +$15.6K
ANAC
8
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$274M 2.89%
5,122,375
+923,855
+22% +$68.2M
DBVT
9
DBV Technologies
DBVT
$800M
$179M 1.89%
550,956
+4,754
+0.9% +$1.33M
ACOR
10
DELISTED
Acorda Therapeutics
ACOR
$96.8M 1.02%
30,509
+675
+2% +$2.8M
CERS icon
11
Cerus
CERS
$577M
$80.4M 0.85%
13,553,275
– –
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$69.9M 0.74%
3,268,556
+313,482
+11% +$7.01M
NGNE icon
13
Neurogene
NGNE
$646M
$68.4M 0.72%
387,624
+50,257
+15% +$9.77M
NVTA
14
DELISTED
Invitae Corporation
NVTA
$67.1M 0.71%
6,554,967
– –
ONC
15
BeOne Medicines Ltd
ONC
$33.8B
$56.1M 0.59%
+1,912,680
New +$54.2M
HRTX icon
16
Heron Therapeutics
HRTX
$91.6M
$55.2M 0.58%
2,907,784
– –
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$45.5M 0.48%
486,565
– –
BCRX icon
18
BioCryst Pharmaceuticals
BCRX
$2.43B
$42.5M 0.45%
15,010,534
+792,755
+6% +$3.51M
IMGN
19
DELISTED
Immunogen Inc
IMGN
$37.9M 0.4%
4,452,445
– –
ONCE
20
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$37.3M 0.39%
1,262,382
– –
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.2B
$35.4M 0.37%
895,422
+44,683
+5% +$1.77M
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
$25.7M 0.27%
533,260
-7,037
-1% -$373K
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$24.5M 0.26%
4,055,876
– –
AAAP
24
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$21.5M 0.23%
615,033
+47,579
+8% +$1.43M
ACHN
25
DELISTED
Achillion Pharmaceuticals
ACHN
$19.1M 0.2%
2,475,515
+475,515
+24% +$3.48M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Baker Bros. Advisors held 139 positions worth $9.48B, down 21% from $12.1B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Baker Bros. Advisors withdrew a net $1.26B in Q1 2016, closing 5 positions and reducing 8 holdings. Its most notable exit was DYAX CORPORATION, an estimated $313M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 73% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in BeOne Medicines Ltd worth $56.1M.

  • Baker Bros. Advisors's largest Q1 2016 buy was BeOne Medicines Ltd: 1,912,680 shares worth $56.1M.
  • Baker Bros. Advisors added most to Incyte in Q1 2016, an estimated $300M increase.
  • Baker Bros. Advisors's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $12M.
  • Baker Bros. Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $313M.
  • Baker Bros. Advisors's ten largest holdings make up 79% of its $9.48B portfolio in Q1 2016.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q1 2016.
  • Baker Bros. Advisors's portfolio value fell 21% quarter-over-quarter to $9.48B.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.